Rate My Professor Peter Dargaville

Dargaville's research centers on innovative therapies for neonatal lung disease in preterm infants, including the pioneering Hobart Method—a less invasive technique for surfactant administration in respiratory distress syndrome that has gained international adoption, reducing chronic lung disease rates and enhancing long-term outcomes. He co-invented the patented OxyGenie automated oxygen-control algorithm, now licensed for SLE ventilators and honored with the Queen’s Award for Enterprise: Innovation. As chief investigator for NHMRC-funded multinational trials such as OPTIMIST-A on minimally invasive surfactant therapy and PLUSS on intratracheal budesonide mixed with surfactant, he leads the AUTOPIA program for automated oxygen titration. With over 140 publications, including landmark JAMA articles on OPTIMIST-A two-year outcomes (2023) and PLUSS results (2024), his contributions have significantly advanced preterm infant respiratory support worldwide.